Opendata, web and dolomites


A cancer vaccine to boost body’s natural defences to fight chordoma and head and neck cancer

Total Cost €


EC-Contrib. €






 MaxONCO project word cloud

Explore the words cloud of the MaxONCO project. It provides you a very rough idea of what is the project "MaxONCO" about.

fast    agent    genetically    market    group    biotech    drug    patients    treat    compare    anywhere    antigens    grow    breakthrough    opportunity    maxivax    mouth    chordoma    safety    glands    primary    spine    vaccine    line    45    designation    trials    throat    2018    radiotherapy    jobs    maxonco    rate    autologous    profile    25    accounting    rare    occurs    positive    fda    approved    stage    therapy    time    initial    trial    data    usa    globally    initiated    approval    situ    commercialization    sites    limited    orphan    cancers    survived    salivary    benefit    benign    swissmedic    diagnosed    plans    neck    treatment    first    indications    sme    switzerland    efficacy    immune    immuno    immunotherapy    acting    cells    prepare    point    source    care    private    company    head    boost    showed    indication    types    modified    biological    besides    cell    clinical    surgery    track    showing    ind    released    indirect    shown    encouraging    cancer    base    650    skull    drugs    investigational    standard    swiss    perform    develops    employees   

Project "MaxONCO" data sheet

The following table provides information about the project.


Organization address
address: RUE DE LATHEENEE 24
city: GENEVA
postcode: 1206
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 3˙979˙000 €
 EC max contribution 2˙785˙300 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2022-06-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAXIVAX SA CH (GENEVA) coordinator 2˙785˙300.00


 Project objective

MaxiVAX a private Swiss clinical-stage biotech company with a novel cancer immunotherapy product in development (MaxONCO) will perform two Phase 2 clinical trials in two indications (Head & Neck, and Chordoma) and prepare the commercialization of MaxONCO, its first immuno-therapy product. The objective of the Phase II clinical trials is to demonstrate efficacy and safety of MaxONCO in the patients treated and compare the results to the current standard of care. MaxONCO is a biological product acting as a cancer vaccine and composed of (i) an immune boost agent released in situ by a genetically modified cell line and (ii) cancer autologous cells, which are the source of antigens. A Phase 1 trial in 25 patients with a range of cancer types at an advanced stage showed encouraging efficacy data and a benign safety profile of the treatment. Head and Neck cancer is a group of cancers that develops in the areas of the head and neck which include the mouth, throat and salivary glands; accounting for 650,000 new cases in 2018 diagnosed globally. With the approval of Swissmedic, MaxiVAX has initiated the Phase 2 clinical trial to evaluate MaxONCO in 40-45 patients with Head & Neck cancer. The study will be conducted across 4-6 different sites in Switzerland. Encouraging clinical results show that among 4 initial Head & Neck patients treated with MaxONCO all survived beyond the 6-month time point (primary efficacy end point). Chordoma is a rare type of cancer that occurs in the skull base and anywhere along the spine. Besides surgery and radiotherapy that are showing only limited success, there are currently no approved drugs to treat Chordoma. In the Phase 1 clinical trial, MaxONCO, has shown promising effects on chordoma patients. A phase 2 Chordoma clinical trial will be conducted in the EU and USA, under an FDA investigational new drug application (IND). A positive overall response rate in Chordoma would allow MaxONCO to benefit from the breakthrough therapy designation as fast-track market opportunity, Chordoma being an orphan indication. Currently accounting for 8 employees, the company plans to grow up to 25 employees by the end of the SME phase 2 project, creating up to 30 indirect jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAXONCO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAXONCO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TalentVision (2019)


Read More  

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  


Specialized Help from Be My Eyes – harnessing technology to connect companies directly with their blind and visually impaired users

Read More